FIGURE

Fig. 1

ID

ZDB-FIG-160429-13

Publication

Lipscomb et al., 2016 - Dasatinib as a treatment for Duchenne muscular dystrophy

Other Figures

All Figure Page

Back to All Figure Page

Fig. 1

Levels of β-dystroglycan and β-dystroglycan phosphorylated on tyrosine in sapje and sibling larvae. Western blots of lysates of individual 3, 4 and 5 dpf sibling and sapje larvae western blotted with antibodies against phosphorylated β-dystroglycan [p-β-DG, (A) top], non-phosphorylated β-dystroglycan [β-DG, (A) middle] and α-tubulin was used as a loading control [α-tub, (A) bottom]. Numbers represent relative position of molecular weight markers in kDa. (B and C) The integrated density of the blots probed against β-DG and p-β-DG shown in (A), quantified relative to α-tubulin levels in each sample. Graphs show mean + SEM of 12 (B) or 9 (C) samples from three independent experiments in each case. (B) There is a significant decrease in the level of β-dystroglycan in larvae with the sapje mutation at 3, 4 and 5 dpf (unpaired t-tests, 3 dpf: P = 0.0016; 4 dpf: P<0.0001; 5 dpf P < 0.0001). (C) Levels of phosphorylated dystroglycan are slightly increased in sapje at 3 and 4 dpf, but this increase is not statistically significant (P > 0.05). When compared with sibling lysates, levels of phosphorylated dystroglycan at 5 dpf are significantly lower in sapje (P = 0.0007).

Expression Data

Gene:	dag1
Antibodies:	Ab4-dag1 Ab5-dag1
Fish:	WT dmd^{ta222a/ta222a}
Anatomical Term:	whole organism
Stage Range:	Protruding-mouth to Day 5

Expression Detail

Antibody Labeling

Phenotype Data

Fish:	dmd^{ta222a/ta222a}
Observed In:	whole organism
Stage Range:	Protruding-mouth to Day 5

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Hum. Mol. Genet.